join us
CN
Home page
About Us
Profile
Affiliates/Subsidiaries
Development History
Quality Management
Contact Us
Legal Statement
Adverse Reaction Report
Science and Technology
R&D platform
R&D pipeline
Therapeutic Field
International Business
APIs
Finished Products
Medical device
Download product list
Contact
News Center
News & Trends
Public information
News & Trends
06
2018-08
Breaking news! Salubris's super product Taiyi (Ticagrelor) was approved for marketing!
Exciting! Recently, Taiyi (Ticagrelor), a super product in cardiovascular field of Salubris Pharmaceuticals, was approved for marketing, winning the first place and taking the lead in the market.
19
2018-06
Salubris invested in M&A of Huanchen Medical to strengthen the layout of devices in the cardiovascular field
On June 8th, the signing ceremony of Salubris's investment and M&A with Suzhou Huanchen Medical Technology Co., Ltd. was held at Salubris Group Headquarters. Salubris will obtain 100% stock right of Suzhou Huanchen in stages with its own capital of R
30
2018-01
The tide of capital increase welcomes a good start
Recently, Salubris has successively increased its capital and invested in Sichuan Jinjiang Electronic Science and Technology Co., Ltd. ("Jinjiang Electronic") and KingstronBio (Changshu) Co., Ltd. ("KingstronBio").
02
2017-05
Warmly congratulate Salubris on the formal establishment of its first American subsidiary
On May 1, local time in Maryland, USA, Salubris Biotherapeutics, Inc., a wholly-owned subsidiary of Genekey Biotech (Chengdu) Co., Ltd., held its opening ceremony in Gaithersburg, Maryland, USA. Salubris Biotherapeutics, Inc. was the first American s
目前在第
10
页,
共有
10
页,
共有
58
条记录
第一页
上一页
6
7
8
9
10
下一页
最后一页
跳转到
页